2026-01-24 - Analysis Report
**Company Overview**
Align Technology is a medical device company specializing in clear aligners and dental care products.

**Return Rate Comparison**
* Ticker: ALGN
* Cumulative return of review stock: -13.89%
* Cumulative return of comparison stock (S&P 500, VOO): 126.41%
* Divergence: -140.30 (max: 245.70, min: -161.40, relative divergence: 5.20%)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 64.0% | 49.0% | 52.0% | 1.5 | 15.2B |
| 2017-2019  | 80.0% | 50.6% | 54.0% | 1.6 | 20.2B |
| 2018-2020  | 82.0% | 56.1% | 58.0% | 1.5 | 38.7B |
| 2019-2021  | 171.0% | 52.7% | 106.0% | 1.5 | 47.6B |
| 2020-2022  | -67.0% | 73.6% | -74.0% | 1.5 | 15.3B |
| 2021-2023  | -191.0% | 73.6% | -212.0% | 1.7 | 19.9B |
| 2022-2024  | -171.0% | 65.4% | -200.0% | 1.7 | 15.1B |
| 2023-2025  | -63.0% | 59.4% | -138.0% | 1.5 | 11.3B |

**Recent Stock Price Fluctuations**

| Metric | Value    |
|--------|----------|
| Close  | $168.73  |
| SMA 5-Day|  $168.93  |
| SMA 20-Day |  $165.49  |
| SMA 60-Day |  $153.17 |

**RSI, PPO Index Indicators and Delta**

| Indicator     | Value       |
|----------------|-------------|
| Market Risk Indicator (MRI) | 0.70        |
| RSI          | 67.72       |
| PPO          | -0.33       |
| Expected Return (%) | -793.60%    |
| Delta_Previous_Relative_Divergence | -0.10 (-)   |
| Expected Return change | 864.90 (+)  |
| Risk Level     | Medium      |

**Recent News & Significant Events**

* Assessing Align Technology (ALGN) Valuation After Recent Share Price Momentum And Mixed Signals (2026-01-22)
* Align Expands Invisalign To Thailand As Analysts Reassess ALGN Outlook (2026-01-22)
* Align Technology Q4 Preview: Even After A Big Drop In Price, Itâ€™s Too Expensive (ALGN) (2026-01-19)
* Mizuho Maintains "Outperform" Rating for ALGN, Raises Price Target (2026-01-20)
* Align Tech (ALGN) Receives a Hold from UBS (2026-01-21)
* Why Align Technology Stock Popped Today (2025-10-30)

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.17 (~Buy)
- Opinions: 15
- Target Price (avg/high/low): 183.87 / 220.00 / 150.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-05 | 0.78 | $1.00B  |
| 2025-08-06 | 1.72 | $1.01B  |
| 2025-05-08 | 1.27 | $0.98B  |
| 2024-11-05 | 1.55 | $0.98B  |

**Financial Information: Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.00B | 64.20%        |
| 2025-06-30 | $1.01B | 69.94%        |
| 2025-03-31 | $0.98B | 69.45%        |
| 2024-12-31 | $1.00B | 70.03%        |
| 2024-09-30 | $0.98B | 69.72%        |

**Financial Information: Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $3.96B | 1.43% |
| 2025-06-30 | $3.91B | 3.18% |
| 2025-03-31 | $3.79B | 2.46% |
| 2024-12-31 | $3.85B | 2.69% |
| 2024-09-30 | $3.94B | 2.94% |

**Comprehensive Analysis**

Based on the provided data, Align Technology has a strong performance in the medical device sector with a large market capitalization. However, the cumulative return rate of the stock is -13.89%, indicating a decline in value compared to the S&P 500 index. The Alpha and Beta analysis shows a positive Alpha value across all periods, indicating that the stock has outperformed the market, but with a relatively high Beta value, indicating volatility.

The recent stock price fluctuations show a downtrend, with the 60-day SMA being the lowest value at $153.17. The RSI and PPO indicators are neutral, but the expected return is extremely negative, indicating a high risk investment.

The recent news and event analysis suggests a mixed signal from analysts and investors, with some maintaining a positive outlook and others questioning the valuation.

The analyst opinions show a majority consensus of Buy ratings, but with a relatively low mean rating of 2.17, indicating some uncertainty.

The earnings analysis shows a decline in revenue and profit margin across all periods, with some fluctuations in EPS.

The financial information shows a relatively stable capital and profitability across all periods, with an increasing trend in equity and ROE.

Overall, the comprehensive analysis suggests a high risk investment with a potential for short-term volatility, but with a long-term potential for growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.